Aclaris Therapeutics (ACRS)

• Market cap: $199M
• 1 day: -5.64%
• 5 days: -11.54%
• 1 month: -1.6%
• 3 months: 27.78%
• 6 months: 16.46%
• Year to date: -25.81%
• 1 year: 54.62%
• 5 years: -21.7%
• 10 years: -83.35%
• Sector: Healthcare
• Industry: Biotechnology

About: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Employees: 64

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

7% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 28

1.05% less ownership

Funds ownership: 85.89% [Q1] → 84.84% (-1.05%) [Q2]

9% less capital invested

Capital invested by funds: $144M [Q1] → $130M (-$13.3M) [Q2]

11% less funds holding

Funds holding: 108 [Q1] → 96 (-12) [Q2]

33% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 36

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6
• Avg. target: $11
• High target: $16

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Biren Amin	$6	Overweight Assumed	10 Jul 2025
HC Wainwright & Co. Raghuram Selvaraju	$16	Buy Reiterated	25 Jun 2025